Pfizer Accupril “Branded Generic” Plans Challenged By Teva

Pfizer should be required to obtain a supplemental NDA approval for Accupril before marketing a "branded generic" version of the ACE inhibitor, Teva told FDA in a June 9 1citizen petition

More from Archive

More from Pink Sheet